Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

FOLR1 expression has previously been implicated in the pathogenesis of treatment-resistant osteosarcoma. This report demonstrates FOLR1 expression by most osteosarcoma tumors and provides preclinical evidence of robust antitumor activity both in vitro and in vivo against xenograft osteosarcoma models exhibited by FH FOLR1-CART. These data support ongoing efforts for clinical translation of FH FOLR1-CART to an early-phase clinical trial for patients with aggressive osteosarcoma.

Authors

Institutions

Publication Details

Journal
Cancer Research Communications
Published
2025-09-01
DOI
https://doi.org/10.1158/2767-9764.crc-25-0086
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

Christina Root, Cyd N. McKay, Rhonda E. Ries, Michelle Choe et al.
Cancer Research Communications
CAR-T cell therapy research
article

Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

Christina Root, Cyd N. McKay, Rhonda E. Ries, Michelle Choe, Richard Görlick, Raisa Glabman, Sanjay V. Malhotra, Soheil Meshinchi, Sarah J. Menashe, Danielle Kirkey, Lara Emily Davis, Elizabeth T. Loggers, Melia Blankenfeld, Jack H. Peplinski, Grace Hawkins, Isabel Lira, Brianna Wrightson
article en

Abstract

FOLR1 expression has previously been implicated in the pathogenesis of treatment-resistant osteosarcoma. This report demonstrates FOLR1 expression by most osteosarcoma tumors and provides preclinical evidence of robust antitumor activity both in vitro and in vivo against xenograft osteosarcoma models exhibited by FH FOLR1-CART. These data support ongoing efforts for clinical translation of FH FOLR1-CART to an early-phase clinical trial for patients with aggressive osteosarcoma.

Cancer Research CommunicationsVol. 5(9)
Seattle Children's Hospital (US), Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), The University of Texas MD Anderson Cancer Center (US), Oregon Health & Science University (US), Fred Hutch Cancer Center (US), Seattle Children's Hospital (US), Center for Cancer and Blood Disorders (US)
M.J. Murdock Charitable Trust, Fred Hutchinson Cancer Research Center, University of Washington, National Institutes of Health, National Cancer Institute
Openalex Percentile: Top 67%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.